Brainstorm Cell Therapeutics News

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersPredictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved u

BenzingaApr 30 16:31 ET

Brainstorm Cell Therapeutics Executive Leadership Changes

TipRanksApr 17 06:12 ET

BrainStorm Cell Therapeutics Promotes Bob Dagher to Chief Medical Officer

Seeking AlphaApr 17 03:25 ET

Express News | Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn

Moomoo 24/7Apr 17 02:54 ET

BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief

By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited clinical trial. The New York-based company,

WSJApr 16 18:51 ET

BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE

BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE

Dow JonesApr 16 18:33 ET

Express News | Brainstorm Cell Therapeutics Inc - Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors

Moomoo 24/7Apr 16 18:31 ET

Express News | Brainstorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3B Trial of Nurown

Moomoo 24/7Apr 16 18:31 ET

Express News | Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Market Value Rule

Moomoo 24/7Apr 11 06:00 ET

Express News | Brainstorm Cell Therapeutics Announced Peer-reviewed Publication Of Phase 3 Biomarker Data In Muscle And Nerve Suggesting That Debamestrocel Or NurOwn May Impact Key Biomarkers In Amyotrophic Lateral Sclerosis That Are Predictive Of Disease Progression

Moomoo 24/7Apr 10 06:02 ET

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data From NurOwn's® Phase 3 Clinical Trial in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...

PR NewswireApr 10 06:00 ET

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersAcrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $230.5 million. Biophytis (NASD

BenzingaApr 9 08:09 ET

Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket

Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today's pre-market trading after reporting FY23 results. Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per s

BenzingaApr 9 06:05 ET

Express News | Brainstorm Cell Therapeutics Received Written Agreement From FDA, Under Special Protocol Assessment, On Design For Phase 3B Trial Of NurOwn In Amyotrophic Lateral Sclerosis Expected To Start In 2024

Moomoo 24/7Apr 9 06:02 ET

BrainStorm Cell Therapeutics Announces Agreement With FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...

PR NewswireApr 9 06:00 ET

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it...

PR NewswireApr 8 06:00 ET

Brainstorm Cell Q4 EPS $(0.11) Beats $(0.15) Estimate

Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 15.38 percent increase over losses of $(0.

BenzingaApr 1 15:47 ET

12 Health Care Stocks Moving In Monday's Intraday Session

GainersSunshine Biopharma (NASDAQ:SBFM) stock rose 86.3% to $0.11 during Monday's regular session. The company's market cap stands at $11.2 million. Xilio Therapeutics (NASDAQ:XLO) stock rose 25.93% t

BenzingaApr 1 12:31 ET

Brainstorm Cell: Q4 Earnings Insights

Brainstorm Cell (NASDAQ:BCLI) reported its Q4 earnings results on Monday, April 1, 2024 at 08:05 AM.Here's what investors need to know about the announcement.EarningsBrainstorm Cell beat estimated ear

BenzingaApr 1 10:35 ET

Brainstorm Cell Therapeutics 2023 Loss/Shr 40c >BCLI

Brainstorm Cell Therapeutics 2023 Loss/Shr 40c >BCLI

Dow JonesApr 1 08:09 ET